Prometheus Biosciences (RXDX) Stock Forecast, Price Target & Predictions
RXDX Stock Forecast
Prometheus Biosciences stock forecast is as follows: an average price target of $138.57 (represents a -30.69% downside from RXDX’s last price of $199.92) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
RXDX Price Target
RXDX Analyst Ratings
Prometheus Biosciences Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Apr 16, 2023 | Annabel Samimy | Stifel Nicolaus | $200.00 | $114.01 | 75.42% | 0.04% |
Jan 31, 2023 | - | Goldman Sachs | $144.00 | $113.66 | 26.69% | -27.97% |
Dec 08, 2022 | Jeff Jones | Oppenheimer | $125.00 | $117.21 | 6.65% | -37.47% |
Dec 08, 2022 | Gregory Renza | RBC Capital | $111.00 | $117.21 | -5.30% | -44.48% |
Dec 08, 2022 | Julian Harrison | BTIG | $181.00 | $117.21 | 54.42% | -9.46% |
Dec 08, 2022 | Tiago Fauth | Credit Suisse | $142.00 | $117.21 | 21.15% | -28.97% |
Dec 08, 2022 | Julian Harrison | BTIG | $104.84 | $95.80 | 9.44% | -47.56% |
Aug 28, 2022 | Yasmeen Rahimi | Piper Sandler | $67.00 | $49.40 | 35.63% | -66.49% |
Jun 10, 2022 | Yasmeen Rahimi | Piper Sandler | $53.00 | $26.35 | 101.14% | -73.49% |
Prometheus Biosciences Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $199.92 | $199.92 | $199.92 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Jan 31, 2023 | Goldman Sachs | Buy | Buy | Hold |
Dec 08, 2022 | RBC Capital | Outperform | Outperform | Hold |
Dec 08, 2022 | Oppenheimer | Outperform | Outperform | Hold |
Dec 08, 2022 | Credit Suisse | Outperform | Outperform | Hold |
Dec 08, 2022 | BTIG | Buy | Buy | Hold |
Oct 04, 2022 | Oppenheimer | Outperform | Outperform | Hold |
Oct 04, 2022 | RBC Capital | Outperform | Outperform | Hold |
Aug 29, 2022 | Wells Fargo | Overweight | Overweight | Hold |
Aug 28, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Jun 10, 2022 | Piper Sandler | - | Overweight | Initialise |
Prometheus Biosciences Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
PLRX | Pliant Therapeutics | $14.49 | $39.71 | 174.05% | Buy |
APLS | Apellis Pharmaceuticals | $28.56 | $76.13 | 166.56% | Buy |
DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
ETNB | 89bio | $9.29 | $22.00 | 136.81% | Buy |
STOK | Stoke Therapeutics | $13.10 | $30.60 | 133.59% | Buy |
TERN | Terns Pharmaceuticals | $7.10 | $14.25 | 100.70% | Buy |
VKTX | Viking Therapeutics | $63.14 | $100.50 | 59.17% | Buy |
IMVT | Immunovant | $29.42 | $42.83 | 45.58% | Buy |
AKRO | Akero Therapeutics | $32.05 | $46.00 | 43.53% | Buy |
ROIV | Roivant Sciences | $11.53 | $16.21 | 40.59% | Buy |
BPMC | Blueprint Medicines | $91.88 | $109.71 | 19.41% | Buy |
KRYS | Krystal Biotech | $170.85 | $191.00 | 11.79% | Buy |
MDGL | Madrigal Pharmaceuticals | $331.32 | $315.75 | -4.70% | Buy |
AMLX | Amylyx Pharmaceuticals | $5.70 | $5.33 | -6.49% | Buy |
ACLX | Arcellx | $86.44 | $71.57 | -17.20% | Buy |
KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
RXDX | Prometheus Biosciences | $199.92 | $138.57 | -30.69% | Buy |
RXDX Forecast FAQ
Is Prometheus Biosciences a good buy?
Yes, according to 7 Wall Street analysts, Prometheus Biosciences (RXDX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of RXDX's total ratings.
What is RXDX's price target?
Prometheus Biosciences (RXDX) average price target is $138.57 with a range of $67 to $200, implying a -30.69% from its last price of $199.92. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Prometheus Biosciences stock go up soon?
According to Wall Street analysts' prediction for RXDX stock, the company can go down by -30.69% (from the last price of $199.92 to the average price target of $138.57), up by 0.04% based on the highest stock price target, and down by -66.49% based on the lowest stock price target.
Can Prometheus Biosciences stock reach $300?
RXDX's average twelve months analyst stock price target of $138.57 does not support the claim that Prometheus Biosciences can reach $300 in the near future.